Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Clinical trial NCT02553642 · COMPLETED
Trial details
- NCT number
- NCT02553642
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-09-14
- Primary completion
- 2024-04-29
- Enrollment
- 81
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.